SCHEMBL22018234

SCHEMBL22018234

O=C(Nc1cnc2[nH]ccc2c1C1CCCCCCCC1)C1CCCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 5/20 0.49
AAK1 Q2M2I8 2/20 0.47
STK17B O94768 1/20 0.47
ROCK2 O75116 2/20 0.47
ROCK1 Q13464 2/20 0.47
CDK2 P24941 2/20 0.47
PLK4 O00444 1/20 0.47
PDPK1 O15530 1/20 0.47
RPS6KA5 O75582 1/20 0.47
PRKD3 O94806 1/20 0.47
PAK4 O96013 1/20 0.47
PRKCG P05129 1/20 0.47
CDK1 P06493 1/20 0.47
PRKACA P17612 1/20 0.47
RPS6KB1 P23443 1/20 0.47
LTK P29376 1/20 0.47
AKT1 P31749 1/20 0.47
GRK5 P34947 1/20 0.47
PRKCI P41743 1/20 0.47
CDK8 P49336 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853575 1.00 JAK3 (0.49) JAK3AAK1STK17BROCK2ROCK1
SCHEMBL20368735 1.00 JAK3 (0.49) JAK3AAK1STK17BROCK2ROCK1
SCHEMBL22138711 0.84 JAK3 (0.53) JAK3AAK1STK17BROCK2ROCK1
SCHEMBL18399586 0.82 PARP1 (0.47) JAK3AAK1ROCK2ROCK1CDK2
SCHEMBL21157773 0.82 HDAC3 (0.44) JAK3AAK1STK17BCDK2HDAC3
SCHEMBL20368587 0.82 HDAC3 (0.44) JAK3AAK1STK17BCDK2HDAC3
SCHEMBL20368588 0.82 HDAC3 (0.44) JAK3AAK1STK17BCDK2HDAC3
SCHEMBL22018162 0.82 HDAC3 (0.44) JAK3AAK1STK17BCDK2HDAC3
SCHEMBL20368675 0.81 CDK2 (0.46) JAK3AAK1STK17BCDK2CDK1
SCHEMBL21157774 0.81 CDK2 (0.46) JAK3AAK1STK17BCDK2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2020-11-10 US disclosed
US-20200155527-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE HOLDINGS CORPORATION 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200155527-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM2, PIM1, PIM3 JAK3 64/4885AAK1 156/4885STK17B 392/4885
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors PIM2, PIM1, PIM3 JAK3 64/4885AAK1 156/4885STK17B 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.